KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Gross Margin (2018 - 2025)

Ionis Pharmaceuticals has reported Gross Margin over the past 8 years, most recently at 96.09% for Q4 2025.

  • Quarterly results put Gross Margin at 96.09% for Q4 2025, down 222.0% from a year ago — trailing twelve months through Dec 2025 was 96.78% (down 163.0% YoY), and the annual figure for FY2025 was 98.31%, down 10.0%.
  • Gross Margin for Q4 2025 was 96.09% at Ionis Pharmaceuticals, down from 98.51% in the prior quarter.
  • Over the last five years, Gross Margin for IONS hit a ceiling of 99.2% in Q3 2024 and a floor of 107.55% in Q2 2025.
  • Median Gross Margin over the past 5 years was 98.18% (2024), compared with a mean of 87.72%.
  • Biggest five-year swings in Gross Margin: surged 2082bps in 2021 and later plummeted -20570bps in 2025.
  • Ionis Pharmaceuticals' Gross Margin stood at 96.29% in 2021, then grew by 1bps to 97.57% in 2022, then grew by 2bps to 99.06% in 2023, then fell by -1bps to 98.31% in 2024, then dropped by -2bps to 96.09% in 2025.
  • The last three reported values for Gross Margin were 96.09% (Q4 2025), 98.51% (Q3 2025), and 107.55% (Q2 2025) per Business Quant data.